Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Siltuximab in Schizophrenia
NCT02796859Phase 2Unknown
- Start
- May 2016
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Siltuximab Group with Placebo Group (2 arms). Primary endpoint: Change in Cognition at 9 weeks. Status: unknown.
02
Drugs
siltuximab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02796859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796859.